Clinical Trial Update: A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewing Sarcoma [Phase 1]

View source ↗

Summary

Withdrawn: A Phase I clinical trial evaluating the toxicity of allogeneic stem cell transplantation for relapsed or therapy-refractory Ewing sarcoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ewing Sarcoma

Snippet

Sponsor: University of Louisville | Conditions: Ewing Sarcoma | Phase 1 | Status: WITHDRAWN